A038290 Share Price Performance
₩15,890.00
-1330.00 (-7.72%)
Price ₩15,890.00
Share Price₩15,890.00
A038290 Community Narratives
There are no narratives available yet.
Recent A038290 News & Updates
No updates
Macrogen, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -707.60
- Gross Margin
- 33.53%
- Net Profit Margin
- -5.29%
- Debt/Equity Ratio
- 43.3%
Macrogen, Inc. Competitors
About A038290
- Founded
- 1997
- Employees
- 500
- CEO
- WebsiteView website
Macrogen, Inc. provides precision medicine and bio-engineering healthcare services in Korea and internationally. It offers personal healthcare services, including disease prediction and wellness genetic, and DTC genetic testing services; MyPETGENE, a genetic testing service for companion animals; clinical services, such as precision medicine, genetic testing for cancer risk, NGS-based genetic panel lab, and GCLP services; and single cell expert services comprising single cell multi-omics and spatial transcriptome analysis, and single cell (In Situ/spatial) services. The company also provides whole genome, whole exome, transcriptome, epigenome, and metagenome sequencing services; standard sequencing, identification, fragment, customized sequencing, and human ID services; expression, genome, and epigenome microarray; proteomics olink; gene synthesis; DNA and RNA oligo synthesis, and peptide synthesis; and CRISPR knock-in/out, GEM, and mass production services. Macrogen, Inc. was founded in 1997 and is based in Seoul, South Korea.
South Korean Market Performance
- 7 Days: -2.0%
- 3 Months: 20.9%
- 1 Year: 26.1%
- Year to Date: 28.6%
Over the last 7 days, the market has dropped 2.0%, driven by pullbacks in the Materials and Information Technology sectors of 7.0% and 1.3%, respectively. In contrast to the last week, the market is actually up 26% over the past year. As for the next few years, earnings are expected to grow by 22% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading